New Twice-Daily Pain Therapy Heads to Global Markets
Adults managing chronic pain and rheumatoid arthritis may see a sustained-release option as regional approvals proceed.
Updated on Nov. 4, 2026 in Arthritis

GEBRO Holding and Spektus Pharma have signed a global commercialisation partnership for ActraFlex, an extended-release pain management therapy taken twice a day. GEBRO will direct supply and commercialisation across Europe and selected global markets, anchored by Spain, while Spektus will oversee Africa, the Americas, and Asia. The financial terms were not disclosed.
Why it matters
For people living with chronic pain and rheumatoid arthritis, a new sustained-release option could broaden the range of treatments available over time, though approval and availability will depend on regulatory processes in each territory. The partnership splits responsibility by region, so access will vary depending on where a patient lives.
This is a commercial partnership announcement rather than a clinical study, so no trial design, sample size, or measured effect is available. The therapy's clinical performance has not been reported in the source material.
The players
GEBRO Holding
An Austria-based pharmaceutical company focused on specialised medicines, with a therapeutic focus on rheumatoid arthritis and pain management.
Spektus Pharma
A Canada-based pharmaceutical company that developed the AmyloFlex drug-delivery technology integrated into ActraFlex.
The details
ActraFlex combines paracetamol and tramadol into a sustained-release formulation, meaning the two active ingredients are released slowly over time rather than all at once. The therapy integrates Spektus' AmyloFlex drug-delivery technology with GEBRO's Diliban product, which already has an established commercial presence in Spain. GEBRO brings experience in specialised medicines and a particular therapeutic focus on rheumatoid arthritis and pain management, while Spektus will rely on a network of regional pharmaceutical partners to reach its territories.
Timeline
- The partnership agreement was announced on November 4, 2026.
Health Landscape
Sustained-release formulations aim to reduce the number of daily doses needed for ongoing pain control, which is a practical consideration for long-term management of chronic conditions. ActraFlex enters this space as a delivery-technology partnership, which reflects a broader pattern of pharmaceutical companies pairing drug formulations with specialised delivery systems.
If you live with rheumatoid arthritis or chronic pain, this development is worth discussing with your doctor as a possible future option, particularly if you are looking for alternatives to frequent dosing. Availability will depend on regulatory approval in your country, so there is no immediate change to your current care.
The takeaway
A new twice-daily pain therapy is moving toward wider distribution, but it has not yet been reported as approved in any market. If you manage chronic pain or arthritis, ask your physician about current options and what sustained-release treatments may fit your care plan.
Further reading
For more background on how these conditions are managed, explore our Arthritis coverage.


